Compare ATAI & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATAI | OCSL |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2025 | 2007 |
| Metric | ATAI | OCSL |
|---|---|---|
| Price | $4.14 | $12.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $15.88 | $12.63 |
| AVG Volume (30 Days) | ★ 6.9M | 999.8K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1227.60 | N/A |
| 52 Week Low | $1.66 | $10.63 |
| 52 Week High | $6.73 | $14.77 |
| Indicator | ATAI | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 46.06 |
| Support Level | $3.30 | $12.07 |
| Resistance Level | $4.54 | $13.19 |
| Average True Range (ATR) | 0.26 | 0.29 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 23.23 | 11.81 |
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.